PTC Therapeutics, Inc.
NASDAQ:PTCTBiotechnology
+$0.60 today
- Market cap
- $5.04B
- Beta
- 0.55
- P/E (TTM)
- -35.0
- EPS (TTM)
- -$2.26
Volume 1.08M
Average 1.27M
PTCT EBITDA Margin
EBITDA as a percentage of revenue.
PTC Therapeutics, Inc.NASDAQ: PTCT
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 44.9%
EBITDA Margin was 44.9% in Q2 FY2026, up 63.4 pp from a year earlier. On a trailing-twelve-month basis it was 17.2%, down 30.5 pp year over year. Over 3 fiscal years it widened by 103.9 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 10 analysts of 23.5% for the fiscal year ending Dec 2026, down from 51.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 44.9%+22.2 pp QoQ
- Last fiscal yearDec 2025
- 51.3%+66.2 pp YoY
- LTMJun 2026
- 17.2%-30.5 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 51.3%
- Year-over-year change
- +66.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51.3% | +66.2pp |
| FY2024 | 2024-12-31 | -14.9% | +20.3pp |
| FY2023 | 2023-12-31 | -35.2% | +17.4pp |
| FY2022 | 2022-12-31 | -52.6% | +15.7pp |
| FY2021 | 2021-12-31 | -68.4% | — |
EBITDA Margin vs competitors
How PTCT compares with its peers on the latest reported figures
- PTCT's LTM Jun 2026 EBITDA Margin of 17.2% is the 2nd highest of the 8 companies compared; the peer median is -49.3%.
- Its year-over-year change of -30.5 pp is the 5th highest of 8, against a peer median of -0.2 pp.
- Over three fiscal years its change of +103.9 pp compares with a peer median of +70.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 49.9% | -0.2 pp | — | |
| LTM Jun 2026 | 17.2% | -30.5 pp | +103.9 pp | |
| LTM Mar 2026 | 5.7% | +10.5 pp | +34.3 pp | |
| LTM Sep 2026 | -8.0% | -32.9 pp | +5.1 pp | |
| LTM Sep 2026 | -49.3% | -33.5 pp | +8.7 pp | |
| LTM Mar 2026 | -75.2% | +1.0 pp | +105.9 pp | |
| LTM Jun 2026 | -85.7% | +187.2 pp | +377.1 pp | |
| LTM Mar 2026 | -243.2% | -144.4 pp | +3681.3 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding PTCT) | -49.3% | -0.2 pp | +70.1 pp | |
Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 538.59M | 698.8M | 937.82M | 806.78M | 1.73B |
| Cost of Revenue | 32.33M | 44.68M | 65.49M | 57.4M | 71.76M |
| Gross Profit | 506.27M | 654.12M | 872.34M | 749.38M | 1.66B |
| Gross Margin | 94.0% | 93.6% | 93.0% | 92.9% | 95.9% |
| Research & Development | 540.68M | 651.5M | 666.56M | 534.48M | 455.25M |
| Selling, General & Admin | 285.77M | 326M | 332.54M | 300.91M | 347.14M |
| Operating Expenses | 880.71M | 1.1B | 1.31B | 1.05B | 802.39M |
| Depreciation & Amortization | 64.13M | 128.84M | 236.59M | 75.66M | 38.82M |
| EBITDA | (368.18M) | (367.78M) | (330.34M) | (120.46M) | 887.66M |
| EBITDA Margin | -68.4% | -52.6% | -35.2% | -14.9% | 51.3% |
| Operating Income | (374.44M) | (447.41M) | (439.5M) | (302.57M) | 856.51M |
| Operating Margin | -69.5% | -64.0% | -46.9% | -37.5% | 49.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 86.02M | 90.87M | 129.18M | 166.99M | 152.23M |
| Other Income / Expenses | (143.9M) | (140.08M) | (256.61M) | (60.55M) | (159.89M) |
| Income Before Tax | (518.34M) | (587.49M) | (696.11M) | (363.12M) | 696.62M |
| Pre-Tax Margin | -96.2% | -84.1% | -74.2% | -45.0% | 40.3% |
| Income Tax Expense | 5.56M | (28.47M) | (69.51M) | 176K | 13.98M |
| Net Income | (523.9M) | (559.02M) | (626.6M) | (363.3M) | 682.64M |
| Net Margin | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
| EPS (Basic) | (7.43) | (7.79) | (8.37) | (4.73) | 8.58 |
| EPS (Diluted) | (7.43) | (7.79) | (8.37) | (4.73) | 7.78 |
| Weighted Avg Shares | 70.47M | 71.73M | 74.84M | 76.85M | 79.53M |
| Weighted Avg Shares (Diluted) | 70.47M | 71.73M | 74.84M | 76.85M | 88.31M |
PTC Therapeutics, Inc.
NASDAQ:PTCT
Intrinsic Alpha fair value
Locked
Current Price
$60.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.